Omeros(OMER),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OMER Omeros

Market Closed 09-04 16:00:00 EDT

18.95

-0.16

-0.84%

盘后19.03

+0.08+0.42%

19:30 EDT

High19.23	Low18.90	Vol892.19K
Open19.00	D1 Closing19.11	Amplitude1.73%
Mkt Cap1.37B	Tradable Cap1.29B	Total Shares72.38M
T/O17.01M	T/O Rate1.31%	Tradable Shares68.26M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OMER","market":"US","secType":"STK","nameCN":"Omeros","latestPrice":18.95,"timestamp":1788552000000,"preClose":19.11,"halted":0,"volume":892192,"hourTrading":{"tag":"盘后","latestPrice":19.03,"preClose":18.95,"latestTime":"19:30 EDT","volume":71315,"amount":1351441.3192,"timestamp":1788564603087,"change":0.08,"changeRate":0.004222,"amplitude":0.013108},"delay":0,"changeRate":-0.008372579801151237,"floatShares":68258040,"shares":72375355,"eps":1.571234,"marketStatus":"Market Closed","change":-0.16,"latestTime":"09-04 16:00:00 EDT","open":19,"high":19.23,"low":18.9,"amount":17007670.520064,"amplitude":0.017268,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.571234,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788854400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1254974400000,"exchange":"NASDAQ","adjPreClose":19.11,"preHourTrading":{"tag":"盘前","latestPrice":18.98,"preClose":19.11,"latestTime":"09:29 EDT","volume":4210,"amount":80212.94476,"timestamp":1788528599999,"change":-0.13,"changeRate":-0.006803,"amplitude":0.019362},"postHourTrading":{"tag":"盘后","latestPrice":19.03,"preClose":18.95,"latestTime":"19:30 EDT","volume":71315,"amount":1351441.3192,"timestamp":1788564603087,"change":0.08,"changeRate":0.004222,"amplitude":0.013108},"volumeRatio":0.634263,"impliedVol":0.5621,"impliedVolPercentile":0.0397},"requestUrl":"/m/hq/s/OMER/tweets","defaultTab":"tweets","newsList":[{"id":"2664898506","title":"Top Omeros Executive Makes Eye-Catching Move With Insider Stock Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2664898506","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664898506?lang=en_us&edition=fundamental","pubTime":"2026-09-02 10:08","pubTimestamp":1788314921,"startTime":"0","endTime":"0","summary":"New insider activity at Omeros ( ($OMER) ) has taken place on September 1, 2026. Omeros Corporation’s Vice President and General Counsel, Cancelmo ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-omeros-executive-makes-eye-catching-move-with-insider-stock-sale-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-omeros-executive-makes-eye-catching-move-with-insider-stock-sale-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664276869","title":"Omeros VP, General Counsel Peter B. Cancelmo Sells USD 927,167 of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2664276869","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664276869?lang=en_us&edition=fundamental","pubTime":"2026-09-02 04:41","pubTimestamp":1788295298,"startTime":"0","endTime":"0","summary":"Omeros VP, General Counsel Peter B. Cancelmo sells USD 927,167 of common sharesOmeros VP, General Counsel Peter B. Cancelmo sold 50,000 shares on Aug. 28 and Aug. 31.Sales priced at USD 18.65 and USD ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL576nDd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Omeros VP, General Counsel Peter B. Cancelmo Sells USD 927,167 of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663013098","title":"Omeros Director Arnold C. Hanish Sells USD 189,713 of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2663013098","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663013098?lang=en_us&edition=fundamental","pubTime":"2026-08-29 04:32","pubTimestamp":1787949145,"startTime":"0","endTime":"0","summary":"Omeros director Arnold C. Hanish sells USD 189,713 of common sharesOmeros director Arnold C. Hanish sold 15,000 common shares on Aug. 26-27 at prices around USD 18.53 to USD 19.02.Sales followed optio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL2hqLnb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Omeros Director Arnold C. Hanish Sells USD 189,713 of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662799996","title":"Omeros VP Finance, CAO David J. Borges Reports Disposal of Common Shares Worth $206,935.60","url":"https://stock-news.laohu8.com/highlight/detail?id=2662799996","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662799996?lang=en_us&edition=fundamental","pubTime":"2026-08-26 16:55","pubTimestamp":1787734556,"startTime":"0","endTime":"0","summary":"Omeros VP Finance, CAO David J. Borges reports disposal of common shares worth $206,935.60Omeros VP, Finance & CAO David J. Borges sold 10,906 shares of common stock in late August.Sales priced at USD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nNDL5TFvxH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Omeros VP Finance, CAO David J. Borges Reports Disposal of Common Shares Worth $206,935.60","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661215383","title":"Insider Shake-Up at Omeros as Key Director Sells Off a Chunk of Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2661215383","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661215383?lang=en_us&edition=fundamental","pubTime":"2026-08-22 10:09","pubTimestamp":1787364579,"startTime":"0","endTime":"0","summary":"New insider activity at Omeros ( ($OMER) ) has taken place on August 21, 2026. Director Thomas Cable has recently trimmed his stake in Omeros, sell...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/insider-shake-up-at-omeros-as-key-director-sells-off-a-chunk-of-shares-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/insider-shake-up-at-omeros-as-key-director-sells-off-a-chunk-of-shares-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661290739","title":"Omeros Director Thomas J. Cable Disposes of 15,000 Common Shares for $276,772.50","url":"https://stock-news.laohu8.com/highlight/detail?id=2661290739","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661290739?lang=en_us&edition=fundamental","pubTime":"2026-08-22 05:34","pubTimestamp":1787348098,"startTime":"0","endTime":"0","summary":"Omeros director Thomas J. Cable disposes of 15,000 common shares for $276,772.50Omeros director Thomas J. Cable sold 15,000 common shares on Aug. 20, 2026 at an average USD 18.45.He exercised two stoc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL7wJYJJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Omeros Director Thomas J. Cable Disposes of 15,000 Common Shares for $276,772.50","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660415016","title":"Omeros Director Joseph L. Schocken Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2660415016","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660415016?lang=en_us&edition=fundamental","pubTime":"2026-08-19 09:45","pubTimestamp":1787103927,"startTime":"0","endTime":"0","summary":"Omeros director Joseph L. Schocken files initial beneficial ownership statementOmeros director Joseph L. Schocken reported 528,082 common shares in an initial SEC Form 3 filing dated Aug. 12.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omeros Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDLfsRZp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660455737","title":"Why Omeros (OMER) Is Up 27.5% After Swinging To Profitability And Completing Share Buyback","url":"https://stock-news.laohu8.com/highlight/detail?id=2660455737","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660455737?lang=en_us&edition=fundamental","pubTime":"2026-08-18 08:30","pubTimestamp":1787013007,"startTime":"0","endTime":"0","summary":"Omeros Corporation recently reported second-quarter and half-year 2026 results showing a move from net losses to net income of US$13.23 million and US$69.29 million respectively, while also completing a share repurchase of 843,187 shares for US$9.87 million under its December 2025 buyback program.\nAlongside this earnings turnaround, Omeros expanded its board to nine members and added veteran financier Joseph Schocken to both the board and audit committee, potentially influencing capital...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros/news/why-omeros-omer-is-up-275-after-swinging-to-profitability-an","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-omer/omeros/news/why-omeros-omer-is-up-275-after-swinging-to-profitability-an","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DECU","GXDW","FEBU","RGLO","VOTE","OMER","JOYT","BK4007","PMDE","VGFPF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660278430","title":"Omeros VP Finance, CAO David J. Borges Sells 5,000 Shares Worth $84,750","url":"https://stock-news.laohu8.com/highlight/detail?id=2660278430","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660278430?lang=en_us&edition=fundamental","pubTime":"2026-08-18 07:43","pubTimestamp":1787010193,"startTime":"0","endTime":"0","summary":"Omeros VP Finance, CAO David J. Borges sells 5,000 shares worth $84,750Omeros: VP, Finance and CAO David J. Borges exercised stock options for 5,000 shares on Aug. 13, 2026 at USD 3.93.He sold 5,000 s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL2mvZyL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Omeros VP Finance, CAO David J. Borges Sells 5,000 Shares Worth $84,750","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OMER"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659499201","title":"Scienture Q2 Revenue Surges on Rezenopy Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2659499201","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659499201?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:17","pubTimestamp":1786709821,"startTime":"0","endTime":"0","summary":"Scienture Q2 revenue surges on REZENOPY launchOverviewUS specialty pharma firm's Q2 revenue rose sharply, driven by commercial launch of REZENOPYQ2 gross margin reached 97.7%, reflecting growing comme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0EN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SCNX","BK4007","ETON","OMER","PTHS","BK4167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659118061","title":"Omeros’ $100 Million Buyback Plan: How Discretionary Repurchases Could Distort Share Price and Heighten Volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2659118061","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659118061?lang=en_us&edition=fundamental","pubTime":"2026-08-14 14:00","pubTimestamp":1786687243,"startTime":"0","endTime":"0","summary":"Omeros Corporation (OMER) has disclosed a new risk, in the Share Price & Shareholder Rights category. Omeros Corporation’s share repurchase program...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/omeros-100-million-buyback-plan-how-discretionary-repurchases-could-distort-share-price-and-heighten-volatility?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/omeros-100-million-buyback-plan-how-discretionary-repurchases-could-distort-share-price-and-heighten-volatility?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OMER","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659319894","title":"Omeros Appoints Veteran Investor Joseph Schocken to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2659319894","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659319894?lang=en_us&edition=fundamental","pubTime":"2026-08-14 05:08","pubTimestamp":1786655309,"startTime":"0","endTime":"0","summary":"The latest update is out from Omeros ( ($OMER) ). On August 12, 2026, Omeros Corporation expanded its Board of Directors from eight to nine members...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/omeros-appoints-veteran-investor-joseph-schocken-to-board?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/omeros-appoints-veteran-investor-joseph-schocken-to-board?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OMER","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659716785","title":"Omeros Appoints Tranceka Capital Founder Joseph Schocken to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2659716785","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659716785?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:17","pubTimestamp":1786652273,"startTime":"0","endTime":"0","summary":"Omeros appoints Tranceka Capital founder Joseph Schocken to boardOmeros expanded its board to nine directors on Aug. 12, 2026, naming private investor Joseph Schocken as a director.Schocken joined the","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL6GsTPH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659516785","title":"Celcuity Posts Narrower-than-Expected Loss as R&D Costs Decreased","url":"https://stock-news.laohu8.com/highlight/detail?id=2659516785","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659516785?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:17","pubTimestamp":1786652236,"startTime":"0","endTime":"0","summary":"Celcuity posts narrower-than-expected loss as R&D costs decreasedOverviewUS biotechnology firm's Q2 adjusted loss per share beat analyst expectationsQ2 adjusted net loss also beat analyst expectations","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A15A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OMER","MEDI","BK4588","BK4585","KURA","BK4505","MEMS","BK4139","CANC","LEGN","CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659264162","title":"ARS Pharmaceuticals Q2 Neffy Revenue Rises as Epinephrine Market Share Doubles","url":"https://stock-news.laohu8.com/highlight/detail?id=2659264162","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659264162?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:13","pubTimestamp":1786651987,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals Q2 neffy revenue rises as epinephrine market share doublesOverviewUS biopharma firm's Q2 neffy net product revenue rose, U.S. epinephrine market share doubled yr/yrCompany posted Q","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A13Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LQDA","SPRY","BK4007","OMER","BK4139","AQST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659119166","title":"U.S. Stocks on the MOVE-EnerSys, Netflix, Salesforce","url":"https://stock-news.laohu8.com/highlight/detail?id=2659119166","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659119166?lang=en_us&edition=fundamental","pubTime":"2026-08-14 00:18","pubTimestamp":1786637899,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-EnerSys, Netflix, SalesforceAugust 13 (Reuters)-The S&P 500 hit an intraday record high on Thursday, boosted by technology stocks, as a drop in crude prices lifted risk ap","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL6N44A14N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WSPC","LESL","OTLK","GLNG","XLC","CSCS","TRUM","RKLB","LNSR","ARX","DERM","MSGS","NEM","CBRS","CRMD","PYXS","ABCL","ABEO","ENS","STUB","TPR","AKAM","AVAH","BIRK","MH","DELL","DIPR","CSCL","IBM","RKLX","DKL","CRM","OPEN","HLIT","OMER","FIVE","HPQ","LWAY","DIOD","SPCE","CGEM","NFLX","LUNR","LUNL","STAA","AGMI","WQTM","CSCO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659315736","title":"Biofrontera Q2 Revenue Rises on Higher Volume, Pricing","url":"https://stock-news.laohu8.com/highlight/detail?id=2659315736","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659315736?lang=en_us&edition=fundamental","pubTime":"2026-08-13 21:01","pubTimestamp":1786626085,"startTime":"0","endTime":"0","summary":"Biofrontera Q2 revenue rises on higher volume, pricingOverviewU.S. biopharmaceutical firm's Q2 revenue grew 33% yr/yr, driven by higher unit volume and pricingNet loss for Q2 narrowed to $0.6 mln from","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0MK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTHS","BK4139","BFRI","OMER","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659151875","title":"CorMedix Beats Q2 Revenue Estimates on DefenCath Growth, Raises FY Adjusted Ebitda Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2659151875","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659151875?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:42","pubTimestamp":1786621337,"startTime":"0","endTime":"0","summary":"CorMedix beatsQ2 revenue estimates on DefenCath growth, raises FY adjusted EBITDA guidanceOverviewUS biopharma firm's Q2 revenue rose, beating analyst expectationsEPS for Q2 beat analyst expectationsC","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0I7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","CANC","MEMS","MEDI","CRMD","LEGN","OMER","BK4007","BK4505","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659915189","title":"Karyopharm Q2 Revenue Falls as License Revenue Drops; Expects Funds to Last into September","url":"https://stock-news.laohu8.com/highlight/detail?id=2659915189","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659915189?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:41","pubTimestamp":1786621315,"startTime":"0","endTime":"0","summary":"Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into SeptemberOverviewCancer drug developer's Q2 revenue declined yr/yr as license and other revenue fellU.S. XPOVIO net pro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0ID:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KPTI","BK4505","OMER","KURA","BK4007","TXMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659159826","title":"Pelthos Therapeutics Q2 Revenue Rises on Zelsuvmi Adoption","url":"https://stock-news.laohu8.com/highlight/detail?id=2659159826","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659159826?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:20","pubTimestamp":1786620006,"startTime":"0","endTime":"0","summary":"Pelthos Therapeutics Q2 revenue rises on Zelsuvmi adoptionOverviewU.S. biopharmaceutical firm's Q2 net product revenue grew 45% quarter-over-quarterNet loss for Q2 narrowed compared to Q1, adjusted EB","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0H6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OMER","PTHS","PLX","BK4007","LQDA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.omeros.com","stockEarnings":[{"period":"1week","weight":0.0183},{"period":"1month","weight":0.498},{"period":"3month","weight":0.9356},{"period":"6month","weight":0.6421},{"period":"1year","weight":3.5335},{"period":"ytd","weight":0.1033}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0443},{"period":"6month","weight":0.1455},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1294}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.352941,"avgChangeRate":-0.012739},{"month":2,"riseRate":0.588235,"avgChangeRate":0.056959},{"month":3,"riseRate":0.588235,"avgChangeRate":0.084424},{"month":4,"riseRate":0.411765,"avgChangeRate":-0.00729},{"month":5,"riseRate":0.352941,"avgChangeRate":-0.04488},{"month":6,"riseRate":0.294118,"avgChangeRate":0.025891},{"month":7,"riseRate":0.470588,"avgChangeRate":0.076019},{"month":8,"riseRate":0.352941,"avgChangeRate":0.006955},{"month":9,"riseRate":0.352941,"avgChangeRate":-0.001125},{"month":10,"riseRate":0.5,"avgChangeRate":-0.042054},{"month":11,"riseRate":0.647059,"avgChangeRate":0.236058},{"month":12,"riseRate":0.529412,"avgChangeRate":0.065706}],"exchange":"NASDAQ","name":"Omeros","nameEN":"Omeros"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Omeros(OMER),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Omeros(OMER) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Omeros,OMER,Omeros股票,Omeros股票老虎,Omeros股票老虎国际,Omeros行情,Omeros股票行情,Omeros股价,Omeros股市,Omeros股票价格,Omeros股票交易,Omeros股票购买,Omeros股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Omeros(OMER),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Omeros(OMER) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}